KALARIS THERAPEUTICS INC (KLRS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.90-1.02%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KLRS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -71.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
KLRS — litigation filed
Dated 2026-07-17
Other Events. On July 17, 2026, the Company issued a press release announcing positive additional data from its Phase 1a SAD clinical trial of TH103 in treatment-naïve patients with nAMD. Data from the expanded cohorts build on previously reported positive findings from the trial, with additional patients showing improvements in vision and retinal anatomy and further supporting the potential for extended treatment durability after a standard four-dose loading regimen. The expanded Phase 1a SA…
Why it matters: A drop in cash could mean financial trouble and hurt ongoing clinical trials.
Worry ifThe company has more than $90 million in cash. This shows it is financially stable.
Less concerning ifThe company has less than $90 million in cash. This raises concerns about funding operations.
Why it matters: Updates on financial health will show if Kalaris can keep operating and fund trials.
Watch forQ2 earnings report shows cash reserves above $100 million.
Also watch forQ2 earnings report shows cash reserves below $100 million.
Why it matters: Delays may show problems in development and hurt investor trust.
Worry ifPhase 3 clinical trials are initiated by year-end 2027 as planned.
Less concerning ifAny announcement of delays in starting Phase 3 trials.
Why it matters: Successful private placements will boost Kalaris' finances and help its growth plans.
Supportive ifLook for news about private placements that raise a lot of money.
Worry ifFailure to get funding or bad news about financial stability.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$241 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $882 loss on $10,000 · 8.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,958 loss on $10,000 · 69.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Initial data will show how well TH103 works for patients with neovascular AMD. This is key for future trials.
Supportive ifEarly data from the Phase 1b/2 study shows good safety and effectiveness.
Worry ifEarly data shows no big changes in safety or effectiveness for TH103.
Why it matters: Starting Phase 3 trials is a strong signal that TH103 is moving closer to market. This is crucial for Kalaris.
Supportive ifPhase 3 clinical trials for TH103 are initiated by year-end 2027 as planned.
Worry ifPhase 3 trials are delayed or not initiated by year-end 2027.